Pharmacokinetics of Telbivudine in Healthy Subjects and Absence of Drug Interaction with Lamivudine or Adefovir Dipivoxil  

Oleh:

[s.n]

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Antimicrobial Agents and Chemotherapy vol. 50 no. 07 (Jul. 2006), page 2309.
Topik: Pharmacokinetics

Ketersediaan

Perpustakaan FK Nomor Panggil: A21.K, A21.K.2006.03 Non-tandon: 3 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects. Study drugs were administered orally. The pharmacokinetics of telbivudine were characterized by rapid absorption with biphasic disposition. The maximum concentrations in plasma (Cmax) were reached at median times ranging from 2.5 to 3.0 h after dosing. Mean Single-dose Cmax and area under the plasma concentration-time curve from time zero to infinity were 1.1 and 2.9 ug/ml and 7.4 and 21.8 ug. h/ml for the 200- and 600-mg telbivudine doses, respectively. Steady state was reached after daily dosing for 5 to 7 days. The results provide pharmacologic support for combination therapy or therapy switching involving telbivudine, lamivudine, and adefovir dipivoxil for the treatment of chronic hepatitis B virus infection.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali